Shane Havens, MD
Ophthalmology · Omaha, NENPI 1548498447
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,293 of the $6,271 with a category attached, or 84.4%. It is spread thinly across 20 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,473 and has fallen 74.0% since, to $643 in 2025. Among ophthalmology clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 219 payments — averaging $28.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$1K
- AbbVie$1K
- NEW World Medical,inc.$716
- Alcon$646
- Bausch & Lomb Americas Inc.$510
- Sun Pharmaceutical Industries Inc.$441
- plus $2K from 14 others
Across 1 payment — averaging $2000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sight Sciences, Inc.$2K
What the payments were for
- Travel & lodging$92415%
- Food & beverage$5,29384%
- Education$541%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 15 | $1,290 |
| AbbVie(2 entities) | 70 | $1,157 |
| NEW World Medical,inc. | 11 | $716 |
| Alcon | 14 | $646 |
| Bausch & Lomb Americas Inc. | 30 | $510 |
| Sun Pharmaceutical Industries Inc. | 22 | $441 |
| Oyster Point Pharma, Inc. | 11 | $276 |
| Sight Sciences, Inc. | 7 | $242 |
| Rayner Intraocular Lenses Limited | 9 | $224 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $178 |
| Ivantis, Inc | 1 | $144 |
| Optos, Inc. | 1 | $107 |
| Aerie Pharmaceuticals, Inc. | 6 | $91 |
| Novartis | 5 | $88 |
| Kala Pharmaceuticals, Inc. | 2 | $41 |
| Lombart Brothers, Inc. | 1 | $34 |
| Harrow Eye, LLC | 1 | $29 |
| Tarsus Pharmaceuticals, Inc. | 1 | $23 |
| Topcon Healthcare, Inc. | 1 | $18 |
| Rxsight Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,271 in reported general payments places this provider in the 95th percentile of 105 ophthalmology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyzultaLatanoprostene Bunod | 158 | $56,029 |
| LumiganBimatoprost | 103 | $53,232 |
| RestasisCyclosporine | 39 | $36,118 |
| CombiganBrimonidine Tartrate/Timolol | 66 | $22,605 |
| RhopressaNetarsudil Mesylate | 36 | $16,537 |
| RocklatanNetarsudil Mesylat/Latanoprost | 32 | $14,527 |
| Latanoprost | 1,336 | $13,930 |
| Alphagan PBrimonidine Tartrate | 18 | $8,917 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 55 | $8,733 |
| Prednisolone Acetate | 162 | $7,471 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 30 | $7,338 |
| Brimonidine Tartrate | 206 | $6,130 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 552 | $5,939 |
| Travoprost | 40 | $5,368 |
| TafluprostTafluprost/Pf | 15 | $3,599 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $1,157 | $120,873226 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $510 | $56,029158 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $91 | $31,06368 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 105 ophthalmology providers in Nebraska.
Other ophthalmology in Omaha
- Brandon BaartmanOmaha$226K
- Ronald KruegerOmaha$224K
- Lorraine ProvencherOmaha$220K
- Lance KuglerOmaha$41K
- Rao ChunduryOmaha$14K
- Brandon MenkeOmaha$6K
- Sao LiuOmaha$5K
- Michael HalstedOmaha$4K
- Thomas HejkalOmaha$4K
- Sao LiuOmaha$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.